{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:29:15Z","timestamp":1791462555536,"version":"4.3.4"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    Monocarboxylate transporter 8 (MCT8) deficiency is a rare, X-linked disorder arising from mutations in the\n                    <jats:italic>SLC16A2<\/jats:italic>\n                    gene and resulting from dysfunctional thyroid hormone transport. This disorder is characterized by profound neurodevelopmental delay and motor disability due to a lack of thyroid hormone in the brain, and coexisting endocrinological symptoms, due to chronic thyrotoxicosis, resulting from elevated thyroid hormone outside the central nervous system (CNS). In February 2024, we reviewed the published literature to identify relevant articles reporting on the current unmet needs of patients with MCT8 deficiency. There are several main challenges in the diagnosis and treatment of MCT8 deficiency, with decreased awareness and recognition of MCT8 deficiency among healthcare professionals (HCPs) associated with misdiagnosis and delays in diagnosis. Diagnostic delay may also be attributed to other factors, including the complex symptomology of MCT8 deficiency only becoming apparent several months after birth and pathognomonic serum triiodothyronine (T3) testing not being routinely performed. For patients with MCT8 deficiency, multidisciplinary team care is vital to optimize the support provided to patients and their caregivers. Although there are currently no approved treatments specifically for MCT8 deficiency, earlier identification and diagnosis of this disorder enables earlier access to supportive care and developing treatments focused on improving outcomes and quality of life for both patients and caregivers.\n                  <\/jats:p>","DOI":"10.3389\/fped.2024.1444919","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:28:15Z","timestamp":1721629695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review"],"prefix":"10.3389","volume":"12","author":[{"given":"Andrew J.","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Auble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Isaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle P.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sidlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","article-title":"Allan-Herndon-Dudley syndrome","volume-title":"GeneReviews\u00ae","author":"Sarret","year":"1993"},{"key":"B2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.17925\/USE.2016.12.02.90","article-title":"Diagnostic and therapeutic challenges in the Allan\u2014Herndon\u2014Dudley syndrome","volume":"12","author":"Groeneweg","year":"2016","journal-title":"US Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/2042098618792502","article-title":"Pharmacovigilance of medicines for rare and ultrarare diseases","volume":"9","author":"Sardella","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1210\/clinem\/dgad412","article-title":"Parent perspectives on complex needs in patients with MCT8 deficiency: an international, prospective, registry study","volume":"109","author":"van Geest","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","volume-title":"MCT8 Deficiency\/Allan-Herndon-Dudley Syndrome (AHDS)","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-8587(20)30153-4","article-title":"Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study","volume":"8","author":"Groeneweg","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1210\/endrev\/bnz008","article-title":"Thyroid hormone transporters","volume":"41","author":"Groeneweg","year":"2020","journal-title":"Endocr Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.beem.2007.03.009","article-title":"The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome","volume":"21","author":"Schwartz","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-Beta (TRbeta) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12020-020-02603-y","article-title":"Monocarboxylate transporter 8 deficiency: update on clinical characteristics and treatment","volume":"71","author":"van Geest","year":"2021","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"657820","DOI":"10.3389\/fneur.2021.657820","article-title":"Regional difference in myelination in monocarboxylate transporter 8 deficiency: case reports and literature review of cases in Japan","volume":"12","author":"Iwayama","year":"2021","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2147\/NDT.S379703","article-title":"Establishing patient-centered outcomes for MCT8 deficiency: stakeholder engagement and systematic literature review","volume":"19","author":"Wilpert","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B13","volume-title":"About Diagnosing","year":""},{"key":"B14","volume-title":"MCT8 deficiency","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.ymgmr.2022.100879","article-title":"Allan-Herndon-Dudley syndrome in a female patient and related mechanisms","volume":"31","author":"Olivati","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fnins.2020.00380","article-title":"MCT8 deficiency: the road to therapies for a rare disease","volume":"14","author":"Grijota-Martinez","year":"2020","journal-title":"Front Neurosci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2023.06.012","article-title":"Repetitive sleep starts in Allan-Herndon-Dudley syndrome","volume":"147","author":"Solazzi","year":"2023","journal-title":"Pediatr Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ymgme.2021.12.003","article-title":"Movement disorders in MCT8 deficiency\/Allan-Herndon-Dudley Syndrome","volume":"135","author":"Masnada","year":"2022","journal-title":"Mol Genet Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S2213-8587(19)30155-X","article-title":"Effectiveness and safety of the tri-iodothyronine analogue triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial","volume":"7","author":"Groeneweg","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"723750","DOI":"10.3389\/fendo.2021.723750","article-title":"Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development","volume":"12","author":"van Geest","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/me.2010-0095","article-title":"Minireview: thyroid hormone transporters: the knowns and the unknowns","volume":"25","author":"Visser","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4103\/jpn.JPN_135_20","article-title":"Thyroid hormone transporter defect: Allan Herndon Dudley syndrome, masquerading as dyskinetic cerebral palsy","volume":"14","author":"Gowda","year":"2021","journal-title":"J Pediatr Neurosci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4274\/jcrpe.845","article-title":"Newborn screening for congenital hypothyroidism","volume":"5","author":"B\u00fcy\u00fckgebiz","year":"2013","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B24","volume-title":"Hypotonia and Failure to Thrive: What\u2019s Your Next Step?","author":"Tonduti","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1374","DOI":"10.1210\/clinem\/dgab890","article-title":"Neonatal screening for hyperthyroidism proof of concept","volume":"107","author":"Banige","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1089\/thy.2020.0696","article-title":"Measurement of reverse triiodothyronine level and the triiodothyronine to reverse triiodothyronine ratio in dried blood spot samples at birth may facilitate early detection of monocarboxylate transporter 8 deficiency","volume":"31","author":"Iwayama","year":"2021","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/mdc3.13656","article-title":"Thyroid disorders and movement disorders-A systematic review","volume":"10","author":"Schneider","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.59213\/TP.2023.53215","article-title":"Interpretation, differential diagnosis, and clinical implications of abnormal thyroid function tests in children","volume":"4","author":"Ak\u0131n Ka\u011f\u0131zmanl\u0131","year":"2023","journal-title":"Trends in Pediatrics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1210\/me.2014-1135","article-title":"In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency","volume":"28","author":"Kersseboom","year":"2014","journal-title":"Mol Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415547","article-title":"TRIAC treatment improves impaired brain network function and white matter loss in thyroid hormone transporter Mct8\/Oatp1c1 deficient mice","volume":"23","author":"Reinwald","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1086\/380999","article-title":"A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene","volume":"74","author":"Dumitrescu","year":"2004","journal-title":"Am J Hum Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S0140-6736(04)17226-7","article-title":"Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation","volume":"364","author":"Friesema","year":"2004","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cen.12023","article-title":"Identification, functional analysis, prevalence and treatment of monocarboxylate transporter 8 (MCT8) mutations in a cohort of adult patients with mental retardation","volume":"78","author":"Visser","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10048-021-00660-7","article-title":"First female with Allan-Herndon-Dudley syndrome and partial deletion of X-inactivation center","volume":"22","author":"Quesada-Espinosa","year":"2021","journal-title":"Neurogenetics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1050023","DOI":"10.3389\/fped.2022.1050023","article-title":"Characteristics of Allan-Herndon-Dudley Syndrome in Chinese children: identification of two novel pathogenic variants of the SLC16A2 gene","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Pediatr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/humu.23140","article-title":"Clinical and molecular characteristics of SLC16A2 (MCT8) mutations in three families with the Allan-Herndon-Dudley syndrome","volume":"38","author":"Novara","year":"2017","journal-title":"Hum Mutat"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s11011-019-00464-7","article-title":"Novel mutations in SLC16A2 associated with a less severe phenotype of MCT8 deficiency","volume":"34","author":"Masnada","year":"2019","journal-title":"Metab Brain Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e21771","DOI":"10.7759\/cureus.21771","article-title":"Allan-Herndon-Dudley syndrome: a novel pathogenic variant of the SLC16A2 gene","volume":"14","author":"Beheshti","year":"2022","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12887-022-03259-5","article-title":"A novel variant in SLC16A2 associated with typical Allan-Herndon-Dudley syndrome: a case report","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Pediatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.26815\/acn.2021.00423","article-title":"Heterogeneous clinical characteristics of Allan-Herndon-Dudley syndrome with SLC16A2 mutations","volume":"29","author":"Han","year":"2021","journal-title":"Annals of Child Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1507\/endocrj.EJ18-0251","article-title":"Functional analysis of monocarboxylate transporter 8 mutations in Japanese Allan-Herndon-Dudley syndrome patients","volume":"66","author":"Islam","year":"2019","journal-title":"Endocr J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/dmcn.14332","article-title":"Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations","volume":"61","author":"Remerand","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/jme-2022-108864","article-title":"Is there a duty to routinely reinterpret genomic variant classifications?","volume":"49","author":"Watts","year":"2023","journal-title":"J Med Ethics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B45","volume-title":"MCT8 Deficiency (AHDS)","year":""},{"key":"B46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.yjmcc.2004.09.013","article-title":"Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects","volume":"37","author":"Morkin","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1210\/jc.2012-2556","article-title":"Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency","volume":"97","author":"Verge","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1210\/en.2015-1234","article-title":"The thyroid hormone analog DITPA ameliorates metabolic parameters of male mice with Mct8 deficiency","volume":"156","author":"Ferrara","year":"2015","journal-title":"Endocrinology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043452","article-title":"Triac treatment prevents neurodevelopmental and locomotor impairments in thyroid hormone transporter Mct8\/Oatp1c1 deficient mice","volume":"24","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B50","volume-title":"Rescue of Infants With MCT8 Deficiency (DITPA)","year":""},{"key":"B51","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/JOE-17-0113","article-title":"Triiodothyroacetic acid in health and disease","volume":"234","author":"Groeneweg","year":"2017","journal-title":"J Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/en.2012-1628","article-title":"Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8","volume":"154","author":"Horn","year":"2013","journal-title":"Endocrinology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/thy.2022.0562","article-title":"Intracerebroventricular high doses of 3,3\u2019,5-triiodothyroacetic acid at juvenile stages improve peripheral hyperthyroidism and mediate thyromimetic effects in limited brain regions in a mouse model of monocarboxylate transporter 8 deficiency","volume":"33","author":"Grijota-Martinez","year":"2023","journal-title":"Thyroid"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1210\/clinem\/dgab750","article-title":"Long-term efficacy of T3 analogue triac in children and adults with MCT8 deficiency: a real-life retrospective cohort study","volume":"107","author":"van Geest","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e202202968","DOI":"10.5546\/aap.2022-02968.eng","article-title":"Treatment with TRIAC in pediatric patients with MCT8","volume":"121","author":"Gazek","year":"2023","journal-title":"Arch Argent Pediatr"},{"key":"B56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4274\/jcrpe.galenos.2023.2023-10-1","article-title":"Impact of early intervention with triiodothyroacetic acid on peripheral and neurodevelopmental findings in a boy with MCTB deficiency","volume":"16","author":"\u00dcnsal","year":"2024","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B57","unstructured":"Triac Trial II in MCT8 Deficiency Patients"},{"key":"B58","volume-title":"Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) (ReTRIACt)","year":""},{"key":"B59","volume-title":"Egetis submits Expanded Access Program for Emcitate\u00ae in the USA","year":""},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.174645","article-title":"Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome","volume":"9","author":"Salas-Lucia","year":"2024","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1089\/thy.2016.0060","article-title":"Adeno associated virus 9-based gene therapy delivers a functional monocarboxylate transporter 8, improving thyroid hormone availability to the brain of Mct8-deficient mice","volume":"26","author":"Iwayama","year":"2016","journal-title":"Thyroid"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1093\/brain\/awac243","article-title":"Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency","volume":"145","author":"Sundaram","year":"2022","journal-title":"Brain"},{"key":"B63","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1089\/thy.2022.0034","article-title":"AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in a mouse model of MCT8-deficiency","volume":"32","author":"Liao","year":"2022","journal-title":"Thyroid"},{"key":"B64","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000507439","article-title":"The protein translocation defect of MCT8(L291R) is rescued by sodium phenylbutyrate","volume":"9","author":"Braun","year":"2020","journal-title":"Eur Thyroid J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1089\/thy.2022.0612","article-title":"Maternal administration of the CNS-selective sobetirome prodrug Sob-AM2 exerts thyromimetic effects in murine MCT8-deficient fetuses","volume":"33","author":"Valcarcel-Hernandez","year":"2023","journal-title":"Thyroid"},{"key":"B66","doi-asserted-by":"publisher","first-page":"A571","DOI":"10.1016\/j.jval.2017.08.979","article-title":"PSY152. Review of rare disease registries across EU5 countries","volume":"20","author":"Gupta","year":"2017","journal-title":"Value Health"},{"key":"B67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40290-020-00332-1","article-title":"Establishing patient registries for rare diseases: rationale and challenges","volume":"34","author":"Boulanger","year":"2020","journal-title":"Pharmaceut Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117621","article-title":"Allan-Herndon-Dudley syndrome in Hong Kong: implication for newborn screening","volume":"551","author":"Yiu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"B69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S2352-4642(20)30280-7","article-title":"Rethinking complex needs with patient and carer perspectives","volume":"4","author":"Coughlan","year":"2020","journal-title":"Lancet Child & Adolescent Health"},{"key":"B71","volume-title":"Patient-Centered Outcome Measures Initiatives in the Field of Rare Diseases","year":""},{"key":"B72","volume-title":"Egetis submits marketing authorisation application for Emcitate\u00ae for treatment of MCT8 deficiency to the European Medicines Agency","year":""}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1444919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:07:51Z","timestamp":1721981271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1444919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":72,"alternative-id":["10.3389\/fped.2024.1444919"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1444919","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1444919"}}